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A detailed phenotypic analysis of immune cell
populations in the bronchoalveolar lavage fluid of
atopic asthmatics after segmental allergen
challenge
Jonathan S Boomer1, Amit D Parulekar1,2, Brenda M Patterson1, Huiqing Yin-Declue1, Christine M Deppong1,
Seth Crockford1, Nizar N Jarjour3, Mario Castro1 and Jonathan M Green1*

Abstract
Background: Atopic asthma is characterized by intermittent exacerbations triggered by exposure to allergen.
Exacerbations are characterized by an acute inflammatory reaction in the airways, with recruitment of both innate
and adaptive immune cells. These cell populations as well as soluble factors are critical for initiating and controlling
the inflammatory processes in allergic asthma. Detailed data on the numbers and types of cells recruited following
allergen challenge is lacking. In this paper we present an extensive phenotypic analysis of the inflammatory cell
infiltrate present in the bronchoalveolar lavage (BAL) fluid following bronchoscopically directed allergen challenge
in mild atopic asthmatics.
Methods: A re-analysis of pooled data obtained prior to intervention in our randomized, placebo controlled,
double blinded study (costimulation inhibition in asthma trial [CIA]) was performed. Twenty-four subjects
underwent bronchoscopically directed segmental allergen challenge followed by BAL collection 48 hours later. The
BAL fluid was analyzed by multi-color flow cytometry for immune cell populations and multi-plex ELISA for cytokine
detection.
Results: Allergen instillation induced pro-inflammatory cytokines (IL-6) and immune modulating cytokines (IL-2, IFNγ, and IL-10) along with an increase in lymphocytes and suppressor cells (Tregs and MDSC). Interestingly,
membrane expression of CD30 was identified on lymphocytes, especially Tregs, but not eosinophils. Soluble CD30
was also detected in the BAL fluid after allergen challenge in adult atopic asthmatics.
Conclusions: After segmental allergen challenge of adult atopic asthmatics, cell types associated with a proinflammatory as well as an anti-inflammatory response are detected within the BAL fluid of the lung.
Keywords: T lymphocyte, CD30 expression, Segmental allergen challenge, Asthma

Background
Asthma is a complex immunological disease affecting approximately 8-10% of the population of the United States
[1-3]. The pathology of asthma includes pulmonary
inflammation, airway eosinophilia, mucus hypersecretion
and airway hyperreactivity (AHR), induced by specific and
nonspecific stimuli which lead to an inappropriate Th2
* Correspondence: jgreen@wustl.edu
1
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Full list of author information is available at the end of the article

response [1-3]. T lymphocytes of a Th2 type secrete IL-3,
IL-4, IL-5, IL-9, and IL-13 [1-3], cytokines which play important roles in Th2 lymphocyte survival, B cell isotype
switching to IgE and mast cell, basophil and eosinophil
differentiation and survival [1-4]. This complex inflammatory cascade is controlled by soluble factors as well as interactions between cell types involving surface receptors
such as CD80/86 on dendritic cells (DC) and CD28/
CTLA-4 on T cells [5-9], ultimately resulting in the
asthma phenotype [1-3].

© 2013 Boomer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Although inflammation is critical to the pathogenesis
of asthma, the exact cell types present in the lung and
their differentiation state remain not well defined. In this
report, we characterized the immune cell populations
and cytokines present within the lungs of mild atopic
asthmatics that underwent bronchoscopy with bronchoalveolar lavage (BAL) after segmental allergen challenge
(SAC). We detected an increase in pro-inflammatory cytokines (IL-6) and immune modulating cytokines (IL-2,
IFN-γ and IL-10) along with an increase in lymphocytes
and the suppressor cells, regulatory T (Treg) and myeloid derived suppressor cells (MDSC). Although we did
not detect expression of CD30 on eosinophils, we did
detect significant membrane expression of CD30 on
Tregs and the presence of sCD30 in the BAL fluid of
adult atopic asthmatics.

Methods
Data collected from the Costimulation Inhibition in
Asthma (CIA) trial (ClinicalTrials.gov NCT00784459)
[10] was pooled and re-analyzed for this manuscript. For
detailed methods and a description of the participant
population and inclusion/exclusion criteria, please refer
to reference [10]. In brief, nonsmoking males and females between 18 and 50 years of age with previously diagnosed mild asthma by NAEPP guidelines were
identified. At screening, participants underwent skin
prick testing of cat allergen extract, short ragweed allergen extract (Ambrosia artemisiifolia), and standardized
dust mite allergen extracts (Dermatophagoides farinae
and/or Dermatophagoides pteronyssinus) (all from Greer
Laboratories, Lenoir NC) to determine their reactivity
using standard methods [10-13] (Table 1). Eligible participants underwent bronchoscopy with segmental allergen challenge (SAC) with instillation of 5 ml allergen
solution at a concentration 1000X the minimum skin reactive test dose, with a maximum of 1:100 dilution of
the stock allergen . Repeat bronchoscopy was performed
48 hours later with BAL performed in the same subsegment in which allergen had previously been instilled.
The study was approved by the Washington University
Institutional Review Board.
Table 1 Allergens used for titrated skin prick testing
Cat

1:100000

1:1000000

1:10000000

Total

2

3

5

10

Measurement of BAL total cell counts and differentials

In the research laboratory, total cell counts were determined, cytospins prepared and manual differentials
performed immediately following bronchoscopy [10].
The BAL fluid was centrifuged and the supernatant
concentrated, using Ultracentrifugation Filter Units
(Millipore, Billerica MA), to approximately 1/20th of the
original volume, aliquoted and frozen at −80°C for further analysis.
Flow cytometric analysis

The cell pellet recovered from the BAL was resuspended
in PBS containing 1% BSA and incubated with antibodies directed against the following cell subsets: T cells
were identified as CD4 or CD8, as naïve (CD45RA) or
memory (CD45RO), and surface phenotyped for CD28,
CD25 or CD30. B cells were identified as CD19+. NK
cells were identified as CD56+. Regulatory T cells were
identified by staining with CD4, CD25 and FoxP3. Dendritic cells were identified via lineage cocktail negative
(CD3/CD14/CD16/CD19/CD20/CD56), HLA-DR high
and either CD123+ for plasmacytoid dendritic cells
(pDC), or CD11c+ for myeloid dendritic cells (mDC).
Myeloid derived suppressor cells (MDSC) were identified as lineage cocktail negative, CD33+ and HLA-DR
low. Eosinophils were identified by light scatter properties, CD16 negative and CD11b+. Fluorescently conjugated antibodies were purchased from BD Biosciences
(San Jose, CA), BioLegend (San Diego, CA) or
eBiosciences (San Diego, CA). In brief, 1-2x106 BAL
cells were labeled with fluorescently conjugated antibodies at room temperature for 30 minutes. After labeling, RBC were lysed in 1X RBC lysis buffer (eBioscience)
for 1–2 minutes and extensively washed in FACS wash
(eBioscience). For FoxP3 staining, after surface labeling,
cells were labeled with anti-FoxP3 antibody according
to the manufactures protocol (human FoxP3 kit,
eBioscience). The labeled cells were then analyzed on a
4-color FACSCalibur flow cytometer using CellQuest software (Becton-Dickinson Corporation, Mountainview,
CA). Samples were gated on a lymphocyte gate followed
by a second gate relevant for the population being analyzed (i.e., CD4+) and a minimum of 10,000 gated events
collected. Data was further analyzed using Winlist v7 software (Verity Software Corporation, Topsham, ME).

Ragweed

4

5

2

11

Measurement of cytokine and soluble CD30 levels

D farinae

1

0

1

2

D Pteronyssinus

1

0

0

1

BAL fluid was analyzed for cytokine content using the
Cytokine Bead Array (Th1/Th2/Th17 kit, BD Biosciences) per the manufacturer’s instructions. The soluble
fragment of CD30 (sCD30) was measured by a standard
enzyme-linked immunosorbent assay (ELISA) per the
manufacturer’s directions (human sCD30 ELISA kit,

The dilution of allergen that provoked a positive test during titrated skin prick
testing is shown. Shown is the number of subjects that had a positive test at
the indicated dilution of allergen. 24 subjects were recruited for the initial trial
with pre-randomization data re-analyzed for this study. Adapted from Table E8
(reference [10]).
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Surprisingly, most subjects had no detectable levels of T
cell-derived cytokines even after allergen instillation in
the lung (Figure 1B). An analysis based upon the type of
allergen instilled and/or the dilution of allergen that induced a positive skin test did not yield statistically relevant differences due to the limited number of subjects in
each group (Table 1). These data indicate that the instillation of allergen in the lung induces the infiltration of
inflammatory cells and the production of both proinflammatory and T-cell dependent cytokines.

Abnova, Walnut, CA). The limit of detection of the
CBA is 5 pg/mL while the sCD30 ELISA is 0.3 ng/mL.
Statistical analysis

All data were analyzed using either SAS version 9.3
(SAS Institute, Cary, NC) or Prism version 4 (GraphPad
Software Inc., La Jolla, CA). Outcomes are presented as
the mean ± standard deviation or graphically as individual subject points. A non-parametric two-tailed
Mann–Whitney U test was performed between preand post-SAC data. A 1-way ANOVA (Kruskal-Wallis)
and Dunn’s Multiple Comparison Test for individual
means was performed when analyzing groups of 3 or
more. A p-value <0.05 was considered significant.

Allergen challenge results in recruitment of innate and
adaptive immune cells to the lung

Multi-color flow cytometry was utilized to provide a
more detailed phenotypic analysis of immune cells recovered following allergen challenge. An increase in
CD4+ T cells along with a decrease in CD8+ T cells was
observed 48 hours following allergen challenge (Figure 2).
The innate immune response to allergen has also been
recognized as an important component of asthma [5];
therefore, we determined the recruitment of natural
killer cells (Nk) and dendritic cells (DC) to the lung. No
change in Nk or myeloid dendritic cells (mDC) was observed; however, a small yet significant increase in
plasmacytoid dendritic cells (pDC; 0.5% ± 0.5% vs 3.9%
± 6.8%; p < 0.05) was observed in the BAL fluid after allergen challenge (Figure 2).
To further characterize the inflammatory response in
the lung following allergen challenge, we enumerated
the number of suppressor cells present in the lung.
Regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSC) are important mechanisms for downmodulating immune responses to antigen; interestingly,
both were recruited to the lung following allergen challenge (Tregs: 4.2% ± 2.1% vs 7.0% ± 4.4% [p < 0.001];
MDSCs: 10.4% ± 8.5% vs 20.6% ± 5.9% [p < 0.01])
(Figure 2). In addition to being present in the BAL, this
MDSC population expressed co-stimulatory B7-molecules
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We re-analyzed data from 24 atopic asthmatics that
underwent a bronchoscopy and allergen challenge prior
to randomization in the parent trial [10]. As indicated in
Figure 1, allergen challenge led to an increase in the
total cell number present in the BAL fluid (1.5x105 ±
6.5x104 vs 8.8x105 ± 1.5x106; p < 0.001). There was also
a significant change in the cellular composition, with an
increase in both eosinophils (28.7% ± 26.2%) and neutrophils (4.5% ± 7.3%), along with a decrease in macrophages detected (−32.1% ± 26.0%) (Figure 1).
We measured the concentrations of pro-inflammatory
(IL-6 and TNF) and T cell-derived (IL-10, IL-2, IL-17,
IL-4 and IFN-γ) cytokines in the BAL by multi-plex
ELISA. IL-6, was significantly induced following allergen
challenge (30.8 ± 82.1 vs 311.6 ± 540.0 pg/mL, Figure 1B)
while TNF was only detected in a single subject (< 10
pg/mL, data not shown). The T cell-dependent cytokines
were not detected pre-allergen; however, IL-2 (4.2 ± 8.8
pg/mL), IFN-γ (6.0 ± 19.3 pg/mL) and IL-10 (5.9 ± 18.2
pg/mL) were detected in some of the subjects
(Figure 1B). Neither IL-4 nor IL-17A was observed postallergen challenge in BAL fluid (data not shown).
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Figure 1 Segmental allergen challenge (SAC) induces an inflammatory response detected in the BAL fluid of atopic asthmatics.
In A), total cell counts and differential analysis are presented for BAL fluid obtained pre- and post-SAC. In B), cytokine levels in the BAL fluid
were measured by multiplex ELISA using the Cytokine Bead Array (CBA). Shown is the re-analysis performed on the 24 subjects enrolled in the
randomized, placebo controlled, double blinded Costimulation Inhibition of Asthma (CIA) trial at pre-randomization. In A (right panel), the
average (change in percent cell type) is presented with error bars representing ± the standard deviation with an (* = p < 0.05; ** = p <0.01;
*** = p < 0.001). Each subject is represented by a single circle in the graphs with p values presented. Due to pre-SAC cytokines being below the
detection limit of the assay (5 pg/mL), no statistical analysis was performed for IL-10, IL-2 or IFN-γ.
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Figure 2 Innate and adaptive immune cells are recruited to the BAL fluid after allergen challenge. Cellular populations in the BAL fluid
pre- and post-SAC were labeled with specific fluorophore conjugated antibodies and analyzed by multi-color flow cytometry. The percentages
were calculated as a percent of the lymphocyte gate, with the exception of the DC (plasmacytoid [pDC], myeloid [mDC]) and myeloid derived
suppressor cell (MDSC) subsets which were calculated as a percentage of the lineage cocktail negative gate. Each subject is represented by a
single symbol on the graphs, with p values indicated.

(CD80 12.2% ± 17.4% and CD86 25.7% ± 12.5%,
Additional file 1).
In addition to analyzing the percentage of lymphocyte
populations, we performed an extensive phenotypic analysis of these cell subsets. An increase in the percentage
of CD45RA+ (naïve or effector memory) T cells (1.1% ±
0.6% vs 5.6% ± 5.4%; p < 0.001) CD4+ and CD8+ (13.3%
± 8.7% vs 21.2% ± 13.5%; p < 0.01) T cells was observed
post-allergen challenge along with a reduction in memory (76.8% ± 12.4% vs 70.3% ± 14.8%; p < 0.05) CD8+ T
cells (Figure 3). We detected an increase in the percentage of cells that expressed the activation marker CD25
(IL-2R) for both CD4+ (16.0% ± 7.4% vs 19.8% ±
6.9%; p < 0.001) and CD8+ (0.7% ± 0.8% vs 1.3% ±

1.3%; p < 0.0001) T cells (Figure 3). These data demonstrate that allergen challenge results in the recruitment of activated CD4+ and CD8+ T cells and
innate immune cells along with specific regulatory
cell populations.
CD30 expression in BAL fluid after allergen challenge

CD30 has been shown to be expressed on eosinophils
[14,15], and is associated with Th2 type T lymphocytes
[16] and may correlate with severity of asthma [17,18];
therefore, we analyzed whether CD30 was expressed on
BAL cells and present in the BAL fluid after allergen
challenge. Contrary to some reports in the literature
[14,15], we were unable to detect any CD30 expression
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Figure 3 Expansion in both naïve and activated T cells in the BAL fluid after allergen challenge. T cell subsets in the BAL fluid pre- and
post-SAC were determined by the expression of CD25 (IL-2R; activated), CD45RA (naïve or effector memory) and CD45RO (memory) by multicolor flow cytometry. The percentages were calculated as a percent of either the CD4+ or CD8+ T cell population. Each subject is represented as
a single symbol on the graphs, with p values indicated.
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Discussion
In this study, we took advantage of results originally
obtained in an interventional trial designed to test the
effects of inhibition of T cell costimulation on the response of mild atopic asthmatics to allergen challenge
[10]. Data obtained prior to administration of study drug
provided a comprehensive data set describing the inflammatory response to allergen. We found that allergen
instillation in the airway results in the recruitment of
Eos

A)

both innate and adaptive immune cells to the lung, including populations of suppressor cells. We also
detected elevated expression of CD30, predominantly on
regulatory T cells. Thus, the inflammatory response to
allergen is a complex mixture of cell types.
Clinical and animal studies have supported the role of
T lymphocytes as controllers of the aberrant Th2 initiated response and eosinophils as predominant effectors
that induce asthma symptoms. The most dominant Th2
cytokine in asthma is IL-4 which has a plethora of activity including increasing IgE production, and differentiating T cells from a Th0 to Th2 [21,22]. We detected an
increase in eosinophil percentage yet no significant increase in IL-4 after allergen challenge. Batra et al. determined the peak level of IL-4 is reached within 24 hours
after allergen challenge [23] potentially explaining the
lack of IL-4 detected in our study. In most subjects the
majority of cytokines were below the limits of detection.
This might reflect the extensive dilution that occurs due
to the BAL procedure. Given this limitation, a meaningful biological difference is hard to conclude from these
data.
Asthma is a predominate Th2 disease but there is also
data for Th1 and Th17 responses. Th2 effector responses
in asthma such as eosinophil recruitment, mucus production and AHR are inhibited by IFN-γ which is produced by Th1 T lymphocytes [1]. We detected a
significant increase in IFN-γ as well as neutrophils which
are recruited by IFN-γ [1] after allergen challenge
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on the surface of BAL eosinophils by multi-color flow
cytometry (Figure 4) or by immuno-histochemical staining of cytospins (data not shown) either pre- or postallergen challenge. However, CD30 expression was
detected on a low yet significant percentage of T and B
cells (Figure 4) and by immuno-histochemical staining
of BAL cytospins (data not shown) obtained following
allergen challenge. Of note, the percentage of CD30+
Tregs (22.1% ± 9.1%) was ~10-fold more than detected
on either B cells (2.1% ± 2.8%) or T cells (CD4+ 3.2% ±
2.0%; CD8+ 0.3% ± 0.7%) (Figure 4). Soluble CD30
(sCD30), the cleaved fragment of membrane CD30
[19,20], was quantitated by ELISA in the concentrated
BAL fluid. There was a 4-fold increase in sCD30 protein
in the BAL fluid upon allergen challenge (3.0 ± 1.1 vs
14.1 ± 24.6 in pg/mL; p < 0.05) (Figure 4). These data
identify the presence of CD30 positive lymphocytes, especially Tregs, but not eosinophils, and sCD30 in the
BAL fluid after allergen challenge of atopic asthmatics.
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Figure 4 CD30 expression is detected after allergen challenge in the BAL fluid. In A), eosinophils were analyzed for CD30 expression by
flow cytometry by gating on high side scatter (left panel) followed by gating on CD16 negative cells with eosinophils determined as CD11b+.
Shown are flow cytometry plots for a representative subject with CD30 expression on eosinophils compared to an isotype control (A, right 2
panels). In B) (left panel), membrane CD30 expression was analyzed on lymphocyte populations (CD4+ and CD8+ T cells ● and ○; B cells □ and
Tregs ◊) post-SAC on 7 subjects by multi-color flow cytometry, with p-values determined by 1-way ANOVA (Kruskal-Wallis) with Dunn’s Multiple
Comparison Test for individual means indicated. In B) (right panel), sCD30 was measured in the pre- and post-SAC BAL of 10 subjects by ELISA,
with the p-value indicated.
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(Figure 1A and 1B). Thus, our data supports a role for
both Th2 and IFN-γ responses in asthma.
Allergen challenge in asthmatics induces changes in
both innate and adaptive cellular populations. Although
we did not detect increases in B lymphocytes, a significant
increase in CD4+ T lymphocytes while a significant decrease in CD8+ T lymphocytes were observed (Figure 2).
Furthermore, we observed alterations in T lymphocyte
differentiation including: increases in naïve or effector
memory (CD45RA+) percentages, increased CD25 (IL-2R)
expression, and a decreased memory CD8+ pool after
allergen challenge signifying a T cell response to antigen
[1,24]. This is consistent with mouse models of asthma
where increased levels of IFN-γ inhibit the generation of
memory T cells [25] further contributing to the expansion
of an effector T cell pool [26].
We did not observe differences in Nk cells or myeloid
dendritic cells (mDC), innate cells important in asthma
pathology [5]; however, a significant increase in
plasmacytoid dendritic cells (pDC) was detected after allergen challenge. The recruitment of pDC may be part
of the anti-inflammatory response in asthma [5,27]. In
accordance with this anti-inflammatory response, an increase in regulatory T cells (Treg) as well as increased
IL-10 secretion, a regulatory T and pDC effector cytokine, were detected after allergen challenge (Figures 2
and 1B). Regulatory T cells inhibit allergic responses by
1) suppressing myeloid dendritic cells (mDC) important
for T lymphocyte activation and differentiation, 2)
inhibiting Th1/Th2 and Th17 differentiation, 3)
inhibiting IgE production, 4) preventing T lymphocyte
migration into the lung and 5) inhibiting effector cell
function of mast cells, basophils and eosinophils [5]. Importantly, we further identified an additional innate cell
population termed myeloid derived suppressor cells
(MDSC) as being increased after allergen challenge in
adult atopic asthmatics (Figure 2). Our report is the first
to identify MDSC in the BAL fluid of adult atopic asthmatics after allergen challenge. Interestingly in a mouse
model of asthma, MDSC were shown to recruit regulatory T cells and down modulate T lymphocyte responses
[28]. We also show that MDSC expressed co-stimulatory
ligands, both CD80 and CD86, which have been associated with inducing Th2 T cells [3] as well as producing
IL-10 [29]. Therefore, multiple suppressor cell types are
associated with the anti-inflammatory response detected
in the lung after allergen challenge.
Soluble CD30 is increased in the serum of pediatric
asthma patients when compared to healthy individuals
[18,30] as well as after allergen challenge in our study.
We also detected sCD30 in the serum prior to allergen
challenge (20.3 ± 8.0 ng/mL; data not shown) in adult
atopic asthmatics. The role of soluble CD30 in asthma is
not clear but is thought to block CD30-CD153 induced
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apoptosis and the induction of IgG class switching on B
cells [31]. The presence of sCD30 in the BAL after allergen challenge may play a role in either preventing apoptosis of activated lymphocytes or in their differentiation.
However, the role of sCD30 in asthma is unknown and
requires further study.
Contrary to reports that detected mRNA and low surface expression of CD30 on eosinophils [14,15], we did
not observe any CD30 expression on eosinophils by either flow cytometry (Figure 4A) or immunohistochemistry (data not shown). We did however detect
membrane CD30 on lymphocytes, especially regulatory
T cells, after allergen challenge. CD30 expression on
CD4+ T cells has been associated with IL-4 secretion
[16] while CD30+ eosinophils undergo apoptosis in asthmatics [14,15]. Memory CD8+ T lymphocytes express
CD30 [32], yet in our study the lowest percentage of
CD30+ cells were CD8+ T lymphocytes. This may be
partly explained by the decreased memory pool of CD8+
T cells after allergen challenge (Figure 3). There are no
reports of CD30 expression on regulatory T cells in
human asthma. In mouse model systems of allograft tolerance, a Th2 dominated response like asthma, CD30deficient Tregs failed to reject grafts [33,34]. Due to the
low cellularity of pre-allergen BAL sample, we were unable to measure CD30 expression on lymphocytes in
most subjects. However, in a single subject, the percentage of CD30+ Tregs in the BAL after allergen challenge
increased from 0.04% pre-allergen to 24.6% post-allergen
challenge (data not shown). The role of CD30 expression
on Tregs in asthma remains unclear; however, interaction
between CD30 on the Treg and CD153 on a CD8+ T cell
results in apoptosis of the CD8+ T cell [33,34]. Therefore,
we speculate that CD30+ regulatory T cells and sCD30
play a role in controlling asthma in a CD30-dependent
manner.

Conclusions
Atopic asthmatics increase innate and adaptive immune
cell populations after allergen challenge. In particular, alterations in both the activation and memory state of T
lymphocytes as well as detection of a novel suppressor
cell population termed MDSC. Furthermore, we
detected soluble CD30 and identified significant expression of CD30 on immune cells, most notably on regulatory T cells, not eosinophils in atopic asthmatics after
allergen challenge.
Additional file
Additional file 1: Expression of co-stimulatory ligands (B7) on
MDSC in the BAL fluid of atopic asthmatics. Myeloid derived
suppressor cells (MDSC) in the BAL fluid post-SAC were labeled with
specific fluorophore conjugated antibodies and analyzed by multi-color
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flow cytometry. MDSC were identified by lineage cocktail negative, HLADR low and CD33+. The percent expression of co-stimulatory ligand
expression on MDSC was analyzed by gating on MDSC followed by
analysis of B7-1 (CD80) and B7-2 (CD86). Each subject is represented by a
single symbol on the graphs, with p values indicated.
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